Evidence map›Paper›PMID 35997712›Full record

ReviewCritical reviews in biochemistry and molecular biology2022

What makes functional amyloids work?

Ansgar B Siemer

Open access · greenAbstract readReview
In one paragraph

Review in Critical reviews in biochemistry and molecular biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. An edge β-strand mutation turns ubiquitin into a pore-forming amyloid.Protein science : a publication of the Protein Society · 2026
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Ansgar B SiemerDepartment of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.ORCID 0000-0003-0901-011X
University of Southern California · US

Funding

Structural characterization of A-beta strain variation in AD mouse modelsR01AG061865 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LANGEN, RALF, SIEMER, ANSGAR B · 2018 to 2022
$4.2M
Molecular Mechanism of Huntingtin Misfolding and its Inhibition by Designed and Cellular ProteinsR01NS120704 · NINDS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CHEN, JEANNIE, LANGEN, RALF · 2021 to 2025
$2.9M
Orb2 a functional amyloid in long-term memory: Its structure and how it formsR01GM110521 · NIGMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SIEMER, ANSGAR B · 2015 to 2019
$1.9M
NIA NIH HHS R01 AG061865NIGMS NIH HHS R01 GM110521NINDS NIH HHS R01 NS120704
6 · The paper itself

Abstract

Although first described in the context of disease, cross-β (amyloid) fibrils have also been found as functional entities in all kingdoms of life. However, what are the specific properties of the cross-β fibril motif that convey biological function, make them especially suited for their particular purpose, and distinguish them from other fibrils found in biology? This review approaches these questions by arguing that cross-β fibrils are highly periodic, stable, and self-templating structures whose formation is accompanied by substantial conformational change that leads to a multimerization of their core and framing sequences. A discussion of each of these properties is followed by selected examples of functional cross-β fibrils that show how function is usually achieved by leveraging many of these properties.

Indexed as

AmyloidAmyloidcross-β motifFunctional amyloidprotein aggregationprotein fibrilsstructure–function relationship

Identifiers

PMID35997712
PMCPMC9588633
OpenAlexW4292749481

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.